Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | BRD2 | P25440 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17433536 | 0.85 | BRD4 (0.68) | BRD4BRD2GAASMN1; SMN2PIK3CD | |
| SCHEMBL17433520 | 0.85 | BRD4 (0.68) | BRD4BRD2GAASMN1; SMN2PIK3CD | |
| SCHEMBL9020969 | 0.82 | — | — | |
| SCHEMBL158498 | 0.82 | — | — | |
| SCHEMBL1304391 | 0.81 | — | — | |
| SCHEMBL19954554 | 0.79 | BRD4 (0.54) | BRD4BRD2GAASMN1; SMN2PIK3CD | |
| Methylpyrrolidone SCHEMBL6635657 | 0.77 | BRD4 (0.81) | BRD4BRD2GAASMN1; SMN2PIK3CD | |
| SCHEMBL22885435 | 0.77 | BRD4 (0.52) | BRD4BRD2GAASMN1; SMN2PIK3CD | |
| SCHEMBL17433534 | 0.76 | BRD4 (0.56) | BRD4BRD2GAASMN1; SMN2PIK3CD | |
| Hydrochloric Acid SCHEMBL29044202 | 0.75 | BRD4 (0.61) | BRD4BRD2GAASMN1; SMN2TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1802619-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006027694-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | AP1M1, AP1G1, AP3B1 | BRD4 287/4885BRD2 1462/4885GAA 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.